Olanzapine developmental disorders

Potenza, M.N., Holmes, J.R Kanes, S.J., and McDougle, C.J. (1999) Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders an open-lahel pilot study. / Clin Psychopharmacol 19 37-44. 

The main indications for atypical antipsychotics are the acute and maintenance treatment of schizophrenic disorders, with an emphasis on the treatment of refractory and chronic disorders. However, because of the lower risk of EPS and in particular of tardive dyskinesia, there is a tendency toward a wider range of indications for some of the atypical neuroleptics. Favorable effects in drug-induced psychoses have been demonstrated for olanzapine. Clozapine seems effective in the treatment and relapse prevention of manic episodes and bipolar disorders, and risperidone has been shown to have good efficacy in conduct disorders and in the pervasive developmental disorders. 

In a prospective open 12-week study in eight children, adolescents, and adults with developmental disorders, the most significant adverse effects of olanzapine were increased appetite and weight gain in six patients and sedation in three (31). 

Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006b) A double-blind placebo-controUed pilot study of olanzapine in chUdhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16 541-548. 

---

See also in sourсe #XX -- [ ]

---